BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mazzaferro V, Sposito C, Zhou J, Pinna AD, De Carlis L, Fan J, Cescon M, Di Sandro S, Yi-Feng H, Lauterio A, Bongini M, Cucchetti A. Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma. Gastroenterology. 2018;154:128-139. [PMID: 28989060 DOI: 10.1053/j.gastro.2017.09.025] [Cited by in Crossref: 178] [Cited by in F6Publishing: 170] [Article Influence: 35.6] [Reference Citation Analysis]
Number Citing Articles
1 Gelli M, Sebagh M, Porcher R, Romanelli E, Vibert E, Sa Cunha A, Castaing D, Rosmorduc O, Samuel D, Adam R, Cherqui D. Liver Resection for Early Hepatocellular Carcinoma: Preoperative Predictors of Non Transplantable Recurrence and Implications for Treatment Allocation. Ann Surg 2020;272:820-6. [PMID: 32833755 DOI: 10.1097/SLA.0000000000004259] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Özdemir F, Baskiran A. The Importance of AFP in Liver Transplantation for HCC. J Gastrointest Canc 2020;51:1127-32. [DOI: 10.1007/s12029-020-00486-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
3 Mehta N, Parikh ND, Kelley RK, Hameed B, Singal AG. Surveillance and Monitoring of Hepatocellular Carcinoma During the COVID-19 Pandemic. Clin Gastroenterol Hepatol 2021;19:1520-30. [PMID: 32652308 DOI: 10.1016/j.cgh.2020.06.072] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
4 Chong HH, Yang L, Sheng RF, Yu YL, Wu DJ, Rao SX, Yang C, Zeng MS. Multi-scale and multi-parametric radiomics of gadoxetate disodium-enhanced MRI predicts microvascular invasion and outcome in patients with solitary hepatocellular carcinoma ≤ 5 cm. Eur Radiol 2021;31:4824-38. [PMID: 33447861 DOI: 10.1007/s00330-020-07601-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
5 Liu JKH, Irvine AF, Jones RL, Samson A. Immunotherapies for hepatocellular carcinoma. Cancer Med 2021. [PMID: 34953051 DOI: 10.1002/cam4.4468] [Reference Citation Analysis]
6 Xue J, Cao Z, Cheng Y, Wang J, Liu Y, Yang R, Li H, Jiang W, Li G, Zhao W, Zhang X. Acetylation of alpha-fetoprotein promotes hepatocellular carcinoma progression. Cancer Lett 2020;471:12-26. [PMID: 31811908 DOI: 10.1016/j.canlet.2019.11.043] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
7 Sposito C, Cucchetti A, Mazzaferro V. Reply. Gastroenterology 2018;154:2276-7. [DOI: 10.1053/j.gastro.2018.05.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Tsilimigras DI, Hyer JM, Diaz A, Bagante F, Ratti F, Marques HP, Soubrane O, Lam V, Poultsides GA, Popescu I, Alexandrescu S, Martel G, Workneh A, Guglielmi A, Hugh T, Aldrighetti L, Endo I, Pawlik TM. Synergistic Impact of Alpha-Fetoprotein and Tumor Burden on Long-Term Outcomes Following Curative-Intent Resection of Hepatocellular Carcinoma. Cancers (Basel) 2021;13:747. [PMID: 33670174 DOI: 10.3390/cancers13040747] [Reference Citation Analysis]
9 von Felden J, Villanueva A. Role of Molecular Biomarkers in Liver Transplantation for Hepatocellular Carcinoma. Liver Transpl 2020;26:823-31. [PMID: 32061009 DOI: 10.1002/lt.25731] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
10 Pinter M, Scheiner B, Peck-Radosavljevic M. Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups. Gut 2021;70:204-14. [PMID: 32747413 DOI: 10.1136/gutjnl-2020-321702] [Cited by in Crossref: 25] [Cited by in F6Publishing: 32] [Article Influence: 12.5] [Reference Citation Analysis]
11 Briggs A, Daniele B, Dick K, Evans TRJ, Galle PR, Hubner RA, Lopez C, Siebert U, Tremblay G. Covariate-adjusted analysis of the Phase 3 REFLECT study of lenvatinib versus sorafenib in the treatment of unresectable hepatocellular carcinoma. Br J Cancer 2020;122:1754-9. [PMID: 32265508 DOI: 10.1038/s41416-020-0817-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
12 Qureshi A, Michel M, Lerner J, Dasanu CA. Evolving therapeutic strategies for advanced hepatocellular carcinoma. Expert Opin Pharmacother 2021;:1-12. [PMID: 34252328 DOI: 10.1080/14656566.2021.1953473] [Reference Citation Analysis]
13 Chapman WC, Korenblat KM, Fowler KJ, Saad N, Khan AS, Subramanian V, Doyle MBM, Dageforde LA, Tan B, Grierson P, Lin Y, Xu M, Brunt EM. Hepatocellular carcinoma: Where are we in 2018? Curr Probl Surg 2018;55:450-503. [PMID: 30526875 DOI: 10.1067/j.cpsurg.2018.10.002] [Reference Citation Analysis]
14 Prince D, Liu K, Xu W, Chen M, Sun JY, Lu XJ, Ji J. Management of patients with intermediate stage hepatocellular carcinoma. Ther Adv Med Oncol 2020;12:1758835920970840. [PMID: 33224278 DOI: 10.1177/1758835920970840] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
15 Piñero F, Rubinstein F, Laurent A, Silva M, Cherqui D, Duvoux C. Comment on "Shadows Behind Using Simple Risk Models in Selection of Hepatocellular Carcinoma Patients for Liver Transplantation". Ann Surg 2021;274:e832-3. [PMID: 33214429 DOI: 10.1097/SLA.0000000000004511] [Reference Citation Analysis]
16 Schnitzbauer AA, Filmann N, Adam R, Bachellier P, Bechstein WO, Becker T, Bhoori S, Bilbao I, Brockmann J, Burra P, Chazoullières O, Cillo U, Colledan M, Duvoux C, Ganten TM, Gugenheim J, Heise M, van Hoek B, Jamieson N, de Jong KP, Klein CG, Klempnauer J, Kneteman N, Lerut J, Mäkisalo H, Mazzaferro V, Mirza DF, Nadalin S, Neuhaus P, Pageaux GP, Pinna AD, Pirenne J, Pratschke J, Powel J, Rentsch M, Rizell M, Rossi G, Rostaing L, Roy A, Scholz T, Settmacher U, Soliman T, Strasser S, Söderdahl G, Troisi RI, Turrión VS, Schlitt HJ, Geissler EK. mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors.Ann Surg. 2020;272:855-862. [PMID: 32889867 DOI: 10.1097/SLA.0000000000004280] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
17 Al-Ameri AAM, Wei X, Liu P, Lin L, Shao Z, Xie H, Zhou L, Zheng S, Xu X. Prediction of Early Recurrence of Hepatocellular Carcinoma in Patients with Cirrhosis Who Had Received Deceased Donor Liver Transplantation: A Multicenter Study. Ann Transplant 2019;24:489-98. [PMID: 31427563 DOI: 10.12659/AOT.917296] [Reference Citation Analysis]
18 Talakić E, Janek E, Mikalauskas S, Schemmer P. Liver Transplantation in Malignancies: A Comprehensive and Systematic Review on Oncological Outcome. Visc Med 2021;37:302-14. [PMID: 34540947 DOI: 10.1159/000517328] [Reference Citation Analysis]
19 Hwang S, Song GW, Ahn CS, Kim KH, Moon DB, Ha TY, Jung DH, Park GC, Yoon YI, Lee SG. Quantitative Prognostic Prediction Using ADV Score for Hepatocellular Carcinoma Following Living Donor Liver Transplantation. J Gastrointest Surg 2021. [PMID: 33532981 DOI: 10.1007/s11605-021-04939-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
20 Pennisi G, Celsa C, Giammanco A, Spatola F, Petta S. The Burden of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: Screening Issue and Future Perspectives. Int J Mol Sci 2019;20:E5613. [PMID: 31717576 DOI: 10.3390/ijms20225613] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
21 Lai Q, Vitale A. Transplantation for hepatocellular cancer: pushing to the limits? Transl Gastroenterol Hepatol 2018;3:61. [PMID: 30363754 DOI: 10.21037/tgh.2018.09.07] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
22 Lee S, Kim KW, Jeong WK, Kim M, Choi GH, Choi JS, Song G, Lee S. Gadoxetic acid–enhanced MRI as a predictor of recurrence of HCC after liver transplantation. Eur Radiol 2020;30:987-95. [DOI: 10.1007/s00330-019-06424-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
23 Kow AWC. Transplantation vs liver resection in patients with hepatocellular carcinoma. Transl Gastroenterol Hepatol. 2019;4:33. [PMID: 31231700 DOI: 10.21037/tgh.2019.05.06] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
24 Halazun KJ, Tabrizian P, Najjar M, Florman S, Schwartz M, Michelassi F, Samstein B, Brown RS, Emond JC, Busuttil RW, Agopian VG. Is it Time to Abandon the Milan Criteria?: Results of a Bicoastal US Collaboration to Redefine Hepatocellular Carcinoma Liver Transplantation Selection Policies. Ann Surg. 2018;268:690-699. [PMID: 30048307 DOI: 10.1097/sla.0000000000002964] [Cited by in Crossref: 34] [Cited by in F6Publishing: 15] [Article Influence: 11.3] [Reference Citation Analysis]
25 Ohira M, Tanimine N, Kobayashi T, Ohdan H. Essential updates 2018/2019: Liver transplantation. Ann Gastroenterol Surg 2020;4:195-207. [PMID: 32490333 DOI: 10.1002/ags3.12321] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Bhatti ABH, Naqvi W, Khan NY, Zia HH, Dar FS, Khan ZA, Rana A. Living donor liver transplantation for advanced hepatocellular carcinoma including macrovascular invasion. J Cancer Res Clin Oncol 2021. [PMID: 34117916 DOI: 10.1007/s00432-021-03665-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Kim JM, Kwon CHD, Joh J, Han S, Yoo J, Kim K, Sinn DH, Choi G, Gerber DA, Egawa H, Lee S. ABO-incompatible Living Donor Liver Transplantation With Rituximab and Total Plasma Exchange Does Not Increase Hepatocellular Carcinoma Recurrence. Transplantation 2018;102:1695-701. [DOI: 10.1097/tp.0000000000002154] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
28 Bredt LC, Peres LAB. Artificial neural network for prediction of acute kidney injury after liver transplantation for cirrhosis and hepatocellular carcinoma. Artif Intell Cancer 2021; 2(5): 51-59 [DOI: 10.35713/aic.v2.i5.51] [Reference Citation Analysis]
29 Halazun KJ, Sapisochin G, von Ahrens D, Agopian VG, Tabrizian P. Predictors of outcome after liver transplantation for hepatocellular carcinoma (HCC) beyond Milan criteria. Int J Surg. 2020;82S:61-69. [PMID: 32707331 DOI: 10.1016/j.ijsu.2020.07.029] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Grąt M, Zieniewicz K. Response to the Comment on "Shadows Behind Using Simple Risk Models in Selection of Hepatocellular Cancer Patients for Liver Transplantation". Ann Surg 2021;274:e833-6. [PMID: 33214427 DOI: 10.1097/SLA.0000000000004509] [Reference Citation Analysis]
31 Degroote H, Piñero F, Costentin C, Notarpaolo A, Boin IF, Boudjema K, Baccaro C, Chagas AL, Bachellier P, Ettorre GM, Poniachik J, Muscari F, Di Benedetto F, Duque SH, Salame E, Cillo U, Gadano A, Vanlemmens C, Fagiuoli S, Rubinstein F, Burra P, Cherqui D, Silva M, Van Vlierberghe H, Duvoux C; French-Italian-Belgium and Latin American collaborative group for HCC and liver transplantation. International study on the outcome of locoregional therapy for liver transplant in hepatocellular carcinoma beyond Milan criteria. JHEP Rep 2021;3:100331. [PMID: 34485882 DOI: 10.1016/j.jhepr.2021.100331] [Reference Citation Analysis]
32 Li Y, Zeng YM, Lu YQ, Qin YY, Chen YK. A study for precision diagnosing and treatment strategies in difficult-to-treat AIDS cases and HIV-infected patients with highly fatal or highly disabling opportunistic infections. Medicine (Baltimore) 2020;99:e20146. [PMID: 32443329 DOI: 10.1097/MD.0000000000020146] [Reference Citation Analysis]
33 Müller H, Kniepeiss D, Stauber R, Schrem H, Rauter M, Krause R, Schemmer P. Recovery from COVID-19 following hepatitis C, human immunodeficiency virus infection, and liver transplantation. Am J Transplant 2020;20:3255-6. [PMID: 32492753 DOI: 10.1111/ajt.16107] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
34 Schiavo L, Busetto L, Cesaretti M, Zelber-Sagi S, Deutsch L, Iannelli A. Nutritional issues in patients with obesity and cirrhosis. World J Gastroenterol 2018; 24(30): 3330-3346 [PMID: 30122874 DOI: 10.3748/wjg.v24.i30.3330] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 21] [Article Influence: 7.8] [Reference Citation Analysis]
35 Lerut J, Foguenne M, Lai Q. Hepatocellular cancer selection systems and liver transplantation: from the tower of babel to an ideal comprehensive score. Updates Surg 2021. [PMID: 34003479 DOI: 10.1007/s13304-021-01078-4] [Reference Citation Analysis]
36 Firl DJ, Sasaki K, Agopian VG, Gorgen A, Kimura S, Dumronggittigule W, Mcvey JC, Iesari S, Mennini G, Vitale A, Finkenstedt A, Onali S, Hoppe‐lotichius M, Vennarecci G, Manzia TM, Nicolini D, Avolio AW, Agnes S, Vivarelli M, Tisone G, Ettorre GM, Otto G, Tsochatzis E, Rossi M, Viveiros A, Cillo U, Markmann JF, Ikegami T, Kaido T, Lai Q, Sapisochin G, Lerut J, Aucejo FN; on behalf of the European Hepatocellular Cancer Liver Transplant Study Group. Charting the Path Forward for Risk Prediction in Liver Transplant for Hepatocellular Carcinoma: International Validation of HALTHCC Among 4,089 Patients. Hepatology 2019;71:569-82. [DOI: 10.1002/hep.30838] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
37 Lai Q, Vitale A, Iesari S, Finkenstedt A, Mennini G, Onali S, Hoppe-Lotichius M, Manzia TM, Nicolini D, Avolio AW, Mrzljak A, Kocman B, Agnes S, Vivarelli M, Tisone G, Otto G, Tsochatzis E, Rossi M, Viveiros A, Ciccarelli O, Cillo U, Lerut J;  European Hepatocellular Cancer Liver Transplant Study Group. The Intention-to-Treat Effect of Bridging Treatments in the Setting of Milan Criteria-In Patients Waiting for Liver Transplantation. Liver Transpl. 2019;25:1023-1033. [PMID: 31087772 DOI: 10.1002/lt.25492] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
38 Reddy SHS, Mehta N, Dodge JL, Hakeem AR, Khorsandi SE, Jassem W, Vilca-Melendez H, Cortes-Cerisuelo M, Srinivasan P, Prachalias A, Heneghan MA, Aluvihare V, Suddle A, Miquel R, Rela M, Heaton ND, Menon KV. Liver transplantation for HCC: validation of prognostic power of the RETREAT score for recurrence in a UK cohort. HPB (Oxford) 2021:S1365-182X(21)01628-2. [PMID: 34702624 DOI: 10.1016/j.hpb.2021.09.008] [Reference Citation Analysis]
39 Hafeez Bhatti AB, Qureshi AI, Tahir R, Almas T, Rana A. Liver transplantation for hepatocellular carcinoma: Improving eligibility without compromising outcomes. Ann Med Surg (Lond) 2021;68:102552. [PMID: 34295467 DOI: 10.1016/j.amsu.2021.102552] [Reference Citation Analysis]
40 Liu K, McCaughan GW. How to select the appropriate "neoadjuvant therapy" for hepatocellular carcinoma. Expert Opin Pharmacother 2018;19:1167-70. [PMID: 30011239 DOI: 10.1080/14656566.2018.1498843] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
41 Mehta N, Dodge JL, Grab JD, Yao FY. National Experience on Down-Staging of Hepatocellular Carcinoma Before Liver Transplant: Influence of Tumor Burden, Alpha-Fetoprotein, and Wait Time. Hepatology 2020;71:943-54. [PMID: 31344273 DOI: 10.1002/hep.30879] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 13.7] [Reference Citation Analysis]
42 Bhatti ABH, Qureshi AI, Tahir R, Dar FS, Khan NY, Zia HH, Riyaz S, Rana A. When to call it off: defining transplant candidacy limits in liver donor liver transplantation for hepatocellular carcinoma. BMC Cancer. 2020;20:754. [PMID: 32787864 DOI: 10.1186/s12885-020-07238-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
43 Cucchetti A, Casadei Gardini A. Incorporating alpha-fetoprotein within dimensional criteria for hepatocellular carcinoma transplantation. Hepatobiliary Surg Nutr 2019;8:65-6. [PMID: 30881969 DOI: 10.21037/hbsn.2018.11.02] [Reference Citation Analysis]
44 Ju MR, Yopp AC. Evolving thresholds for liver transplantation in hepatocellular carcinoma: A Western experience. Ann Gastroenterol Surg 2020;4:208-15. [PMID: 32490334 DOI: 10.1002/ags3.12316] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Loglio A, Iavarone M, Viganò M, Orenti A, Facchetti F, Cortinovis I, Lunghi G, Ceriotti F, Occhipinti V, Rumi M, Sangiovanni A, Colombo M, Lampertico P. Minimal increases of serum alpha‐foetoprotein herald HCC detection in Caucasian HBV cirrhotic patients under long‐term oral therapy. Liver Int 2019;39:1964-74. [DOI: 10.1111/liv.14197] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
46 Han JW, Sung PS, Jang JW, Choi JY, Yoon SK. Whole blood viscosity is associated with extrahepatic metastases and survival in patients with hepatocellular carcinoma. PLoS One 2021;16:e0260311. [PMID: 34855786 DOI: 10.1371/journal.pone.0260311] [Reference Citation Analysis]
47 Lubel JS, Roberts SK, Strasser SI, Thompson AJ, Philip J, Goodwin M, Clarke S, Crawford DH, Levy MT, Shackel N. Australian recommendations for the management of hepatocellular carcinoma: a consensus statement. Med J Aust 2021;214:475-83. [PMID: 33314233 DOI: 10.5694/mja2.50885] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
48 Aggarwal A, Te HS, Verna EC, Desai AP. A National Survey of Hepatocellular Carcinoma Surveillance Practices Following Liver Transplantation. Transplant Direct 2021;7:e638. [PMID: 33324743 DOI: 10.1097/TXD.0000000000001086] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Pommergaard HC, Rostved AA, Adam R, Rasmussen A, Salizzoni M, Bravo MAG, Cherqui D, De Simone P, Houssel-Debry P, Mazzaferro V, Soubrane O, García-Valdecasas JC, Prous JF, Pinna AD, O'Grady J, Karam V, Duvoux C, Thygesen LC. Mortality after Transplantation for Hepatocellular Carcinoma: A Study from the European Liver Transplant Registry. Liver Cancer 2020;9:455-67. [PMID: 32999871 DOI: 10.1159/000507397] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
50 Scheiner B, Pomej K, Kirstein MM, Hucke F, Finkelmeier F, Waidmann O, Himmelsbach V, Schulze K, von Felden J, Fründt TW, Stadler M, Heinzl H, Shmanko K, Spahn S, Radu P, Siebenhüner AR, Mertens JC, Rahbari NN, Kütting F, Waldschmidt DT, Ebert MP, Teufel A, De Dosso S, Pinato DJ, Pressiani T, Meischl T, Balcar L, Müller C, Mandorfer M, Reiberger T, Trauner M, Personeni N, Rimassa L, Bitzer M, Trojan J, Weinmann A, Wege H, Dufour JF, Peck-Radosavljevic M, Vogel A, Pinter M. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score. J Hepatol 2021:S0168-8278(21)02100-0. [PMID: 34648895 DOI: 10.1016/j.jhep.2021.09.035] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
51 Jamtani I, Lee KW, Choi Y, Choi Y, Lee JM, Han ES, Hong K, Choi GS, Kim JM, Yi NJ, Hong SK, Byun J, Hong SY, Suh S, Joh JW, Suh KS. Tailored Prediction Model of Survival after Liver Transplantation for Hepatocellular Carcinoma. J Clin Med 2021;10:2869. [PMID: 34203396 DOI: 10.3390/jcm10132869] [Reference Citation Analysis]
52 Akbulut S, Koc C. Do We Need to Be Limited by Matching Milan Criteria for Survival in Living Donor Liver Transplantation? J Gastrointest Cancer 2020;51:1107-13. [PMID: 32857265 DOI: 10.1007/s12029-020-00482-0] [Reference Citation Analysis]
53 Crocetti L, Bozzi E, Scalise P, Bargellini I, Lorenzoni G, Ghinolfi D, Campani D, Balzano E, De Simone P, Cioni R. Locoregional Treatments for Bridging and Downstaging HCC to Liver Transplantation. Cancers (Basel) 2021;13:5558. [PMID: 34771720 DOI: 10.3390/cancers13215558] [Reference Citation Analysis]
54 Meischl T, Rasoul-Rockenschaub S, Győri G, Scheiner B, Trauner M, Soliman T, Berlakovich G, Pinter M. Alpha-fetoprotein-adjusted-to-HCC-size criteria are associated with favourable survival after liver transplantation for hepatocellular carcinoma. United European Gastroenterol J 2021;9:209-19. [PMID: 32741316 DOI: 10.1177/2050640620948665] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Pagano D, Barbera F, Conaldi PG, Seidita A, Di Francesco F, Di Carlo D, Bàrbara M, Tuzzolino F, Luca A, Gruttadauria S. Role of Allelic Imbalance in Predicting Hepatocellular Carcinoma (HCC) Recurrence Risk After Liver Transplant. Ann Transplant 2019;24:223-33. [PMID: 31015392 DOI: 10.12659/AOT.913692] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Cucchetti A, Serenari M, Sposito C, Di Sandro S, Mosconi C, Vicentin I, Garanzini E, Mazzaferro V, De Carlis L, Golfieri R, Spreafico C, Vanzulli A, Buscemi V, Ravaioli M, Ercolani G, Pinna AD, Cescon M. Including mRECIST in the Metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant. Journal of Hepatology 2020;73:342-8. [DOI: 10.1016/j.jhep.2020.03.018] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
57 Frankul L, Frenette C. Hepatocellular Carcinoma: Downstaging to Liver Transplantation as Curative Therapy. J Clin Transl Hepatol. 2021;9:220-226. [PMID: 34007804 DOI: 10.14218/jcth.2020.00037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Brusset B, Dumortier J, Cherqui D, Pageaux GP, Boleslawski E, Chapron L, Quesada JL, Radenne S, Samuel D, Navarro F, Dharancy S, Decaens T. Liver Transplantation for Hepatocellular Carcinoma: A Real-Life Comparison of Milan Criteria and AFP Model. Cancers (Basel) 2021;13:2480. [PMID: 34069594 DOI: 10.3390/cancers13102480] [Reference Citation Analysis]
59 McVey JC, Sasaki K, Firl DJ. Risk assessment criteria in liver transplantation for hepatocellular carcinoma: proposal to improve transplant oncology. Hepat Oncol 2020;7:HEP26. [PMID: 32774836 DOI: 10.2217/hep-2020-0003] [Reference Citation Analysis]
60 Kwong A, Mehta N. Expanding the Limits of Liver Transplantation for Hepatocellular Carcinoma: Is There a Limit? Clin Liver Dis 2021;25:19-33. [PMID: 33978578 DOI: 10.1016/j.cld.2020.08.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
61 Moris D, Shaw BI, McElroy L, Barbas AS. Using Hepatocellular Carcinoma Tumor Burden Score to Stratify Prognosis after Liver Transplantation. Cancers (Basel) 2020;12:E3372. [PMID: 33202588 DOI: 10.3390/cancers12113372] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
62 Biolato M, Galasso T, Marrone G, Miele L, Grieco A. Upper Limits of Downstaging for Hepatocellular Carcinoma in Liver Transplantation. Cancers (Basel) 2021;13:6337. [PMID: 34944957 DOI: 10.3390/cancers13246337] [Reference Citation Analysis]
63 Pirisi M, Leutner M, Romito R, Gaia S. Novel Calculators for Risk Stratification in Hepatocellular Carcinoma: A Concise Review. J Clin Gastroenterol 2020;54:789-94. [PMID: 32773489 DOI: 10.1097/MCG.0000000000001406] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Guerrini GP, Berretta M, Guaraldi G, Magistri P, Esposito G, Ballarin R, Serra V, Di Sandro S, Di Benedetto F. Liver Transplantation for HCC in HIV-Infected Patients: Long-Term Single-Center Experience. Cancers (Basel) 2021;13:4727. [PMID: 34572954 DOI: 10.3390/cancers13184727] [Reference Citation Analysis]
65 Zhou K, Mehta N. Downstaging to Liver Transplant: Success Involves Choosing the Right Patient. Clin Liver Dis 2020;24:665-79. [PMID: 33012452 DOI: 10.1016/j.cld.2020.07.005] [Reference Citation Analysis]
66 Firl DJ, Kimura S, Mcvey J, Hashimoto K, Yeh H, Miller CM, Markmann JF, Sasaki K, Aucejo FN. Reframing the approach to patients with hepatocellular carcinoma: Longitudinal assessment with hazard associated with liver transplantation for HCC (HALTHCC) improves ablate and wait strategy. Hepatology 2018;68:1448-58. [DOI: 10.1002/hep.29907] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
67 Mazzaferro V, Droz dit Busset M, Bhoori S. Alpha-fetoprotein in liver transplantation for hepatocellular carcinoma: The lower, the better: Hepatology Elsewhere. Hepatology 2018;68:775-7. [DOI: 10.1002/hep.29835] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
68 Chagas AL, Mattos AA, Diniz MA, Felga GEG, Boin IFSF, Silva RCMA, Silva RF, Garcia JHP, Lima AS, Coelho JCU, Bittencourt PL, Alves VAF, D'Albuquerque LAC, Carrilho FJ; Brazilian HCC Study Group. Impact of Brazilian expanded criteria for liver transplantation in patients with hepatocellular carcinoma: a multicenter study. Ann Hepatol 2021;22:100294. [PMID: 33276136 DOI: 10.1016/j.aohep.2020.100294] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
69 Yu J, Zhuang L, Liu P, Liu Z, Ling S, Deng Y, Li J, Yang B, Chen Z, Wang Z, Zang Y, Yang Y, Zheng S, Xu X. Long-term outcomes of deceased donor liver transplantation in hepatocellular carcinoma patients with portal vein tumor thrombus: A multicenter study. Eur J Surg Oncol 2021:S0748-7983(21)00684-3. [PMID: 34456082 DOI: 10.1016/j.ejso.2021.08.014] [Reference Citation Analysis]
70 Giacomoni A, Centonze L, Famularo S, Tripepi M, DeCarlis L. Selection of Hepatocellular Carcinoma Patients for Liver Transplantation: Should the Threshold for Expected Oncological Survival Be Lowered? Transplant Direct 2019;5:e459. [PMID: 31723593 DOI: 10.1097/TXD.0000000000000904] [Reference Citation Analysis]
71 Abreu P, Gorgen A, Oldani G, Hibi T, Sapisochin G. Recent advances in liver transplantation for cancer: The future of transplant oncology. JHEP Rep 2019;1:377-91. [PMID: 32039389 DOI: 10.1016/j.jhepr.2019.07.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
72 Mehta N, Bhangui P, Yao FY, Mazzaferro V, Toso C, Akamatsu N, Durand F, Ijzermans J, Polak W, Zheng S, Roberts JP, Sapisochin G, Hibi T, Kwan NM, Ghobrial M, Soin A. Liver Transplantation for Hepatocellular Carcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference. Transplantation 2020;104:1136-42. [DOI: 10.1097/tp.0000000000003174] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
73 Bagante F, Spolverato G, Merath K, Weiss M, Alexandrescu S, Marques HP, Aldrighetti L, Maithel SK, Pulitano C, Bauer TW, Shen F, Poultsides GA, Soubrane O, Martel G, Koerkamp BG, Guglielmi A, Endo I, Pawlik TM. Intrahepatic cholangiocarcinoma tumor burden: A classification and regression tree model to define prognostic groups after resection. Surgery. 2019;166:983-990. [PMID: 31326191 DOI: 10.1016/j.surg.2019.06.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
74 Mehta N. Liver Transplantation Criteria for Hepatocellular Carcinoma, Including Posttransplant Management. Clin Liver Dis (Hoboken) 2021;17:332-6. [PMID: 34136137 DOI: 10.1002/cld.1054] [Reference Citation Analysis]
75 Lai Q, Vitale A, Manzia TM, Foschi FG, Levi Sandri GB, Gambato M, Melandro F, Russo FP, Miele L, Viganò L, Burra P, Giannini EG; Associazione Italiana per lo Studio del Fegato (AISF) HCC Special Interest Group. Platelets and Hepatocellular Cancer: Bridging the Bench to the Clinics. Cancers (Basel) 2019;11:E1568. [PMID: 31618961 DOI: 10.3390/cancers11101568] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
76 Hwang S, Song GW, Ahn CS, Kim KH, Moon DB, Ha TY, Jung DH, Park GC, Yoon YI, Lee SG. Salvage living donor liver transplantation for hepatocellular carcinoma recurrence after hepatectomy: Quantitative prediction using ADV score. J Hepatobiliary Pancreat Sci 2021;28:1000-13. [PMID: 33175453 DOI: 10.1002/jhbp.863] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
77 Mehta N, Dodge JL, Roberts JP, Yao FY. A novel waitlist dropout score for hepatocellular carcinoma - identifying a threshold that predicts worse post-transplant survival. J Hepatol 2021;74:829-37. [PMID: 33188904 DOI: 10.1016/j.jhep.2020.10.033] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
78 Grąt M, Krawczyk M, Wronka KM, Stypułkowski J, Lewandowski Z, Wasilewicz M, Krawczyk P, Grąt K, Patkowski W, Zieniewicz K. Ischemia-reperfusion injury and the risk of hepatocellular carcinoma recurrence after deceased donor liver transplantation. Sci Rep 2018;8:8935. [PMID: 29895820 DOI: 10.1038/s41598-018-27319-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
79 Zhang S, Wang Z, Fan S, Liu T, Yoshida S, Yang S, Liu L, Hou W, Cao L, Wang J, Song Z, Li S, Zhang S, Wang H, Li J, Zheng H, Shen Z. Capecitabine Can Induce T Cell Apoptosis: A Potential Immunosuppressive Agent With Anti-Cancer Effect. Front Immunol 2021;12:737849. [PMID: 34557199 DOI: 10.3389/fimmu.2021.737849] [Reference Citation Analysis]
80 Zhou PY, Yang CP, Tang Z, Yi Y, Liu WR, Tian MX, Huang JL, Gan W, Jiang XF, Liu G, Wang H, Tao CY, Fang Y, Qu WF, Zhou C, Guan RY, Sun BY, Zhou YF, Song SS, Ding ZB, Peng YF, Dai Z, Zhou J, Fan J, Gong GZ, Shi YH, Qiu SJ. Daily decrease of post-operative alpha-fetoprotein by 9% discriminates prognosis of HCC: A multicenter retrospective study. Aging (Albany NY). 2019;11:11111-11123. [PMID: 31829979 DOI: 10.18632/aging.102513] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
81 Schöning W, Öllinger R, Schmelzle M, Pratschke J. [Frontiers in liver transplantation in indication and techniques]. Chirurg 2019;90:102-9. [PMID: 30413847 DOI: 10.1007/s00104-018-0761-8] [Reference Citation Analysis]
82 Grąt M, Krawczyk M, Stypułkowski J, Morawski M, Krasnodębski M, Wasilewicz M, Lewandowski Z, Grąt K, Patkowski W, Zieniewicz K. Prognostic Relevance of a Complete Pathologic Response in Liver Transplantation for Hepatocellular Carcinoma. Ann Surg Oncol 2019;26:4556-65. [PMID: 31520204 DOI: 10.1245/s10434-019-07811-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
83 Di Sandro S, Benuzzi L, Lauterio A, Botta F, De Carlis R, Najjar M, Centonze L, Danieli M, Pezzoli I, Rampoldi A, Bagnardi V, De Carlis L. Single Hepatocellular Carcinoma approached by curative-intent treatment: A propensity score analysis comparing radiofrequency ablation and liver resection. European Journal of Surgical Oncology 2019;45:1691-9. [DOI: 10.1016/j.ejso.2019.04.023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
84 Serra C, Cucchetti A, Felicani C, Mosconi C, De Cinque A, Golfieri R, Andreone P, Ercolani G, Maroni L, Ravaioli M, D'Errico A, Pinna AD, Cescon M. Assessment of Radiofrequency Ablation Efficacy for Hepatocellular Carcinoma by Histology and Pretransplant Radiology. Liver Transpl 2019;25:88-97. [PMID: 30415500 DOI: 10.1002/lt.25381] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
85 Tan DJH, Wong C, Ng CH, Poh CW, Jain SR, Huang DQ, Muthiah MD. A Meta-Analysis on the Rate of Hepatocellular Carcinoma Recurrence after Liver Transplant and Associations to Etiology, Alpha-Fetoprotein, Income and Ethnicity. J Clin Med 2021;10:E238. [PMID: 33440759 DOI: 10.3390/jcm10020238] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
86 Toniutto P, Fumolo E, Fornasiere E, Bitetto D. Liver Transplantation in Patients with Hepatocellular Carcinoma beyond the Milan Criteria: A Comprehensive Review. J Clin Med 2021;10:3932. [PMID: 34501381 DOI: 10.3390/jcm10173932] [Reference Citation Analysis]
87 Cullaro G, Rubin J, Mehta N, Yao F, Verna EC, Lai JC. Sex-Based Disparities in Hepatocellular Carcinoma Recurrence After Liver Transplantation. Transplantation 2020. [PMID: 33323764 DOI: 10.1097/TP.0000000000003575] [Reference Citation Analysis]
88 Federico P, Petrillo A, Giordano P, Bosso D, Fabbrocini A, Ottaviano M, Rosanova M, Silvestri A, Tufo A, Cozzolino A, Daniele B. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives. Cancers (Basel) 2020;12:E3025. [PMID: 33080958 DOI: 10.3390/cancers12103025] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
89 Muhammad H, Tehreem A, Ting PS, Gurakar M, Li SY, Simsek C, Alqahtani SA, Kim AK, Kohli R, Gurakar A. Hepatocellular Carcinoma and the Role of Liver Transplantation: A Review. J Clin Transl Hepatol 2021;9:738-48. [PMID: 34722189 DOI: 10.14218/JCTH.2021.00125] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
90 Berenguer M, Burra P, Ghobrial M, Hibi T, Metselaar H, Sapisochin G, Bhoori S, Kwan Man N, Mas V, Ohira M, Sangro B, van der Laan LJW. Posttransplant Management of Recipients Undergoing Liver Transplantation for Hepatocellular Carcinoma. Working Group Report From the ILTS Transplant Oncology Consensus Conference. Transplantation 2020;104:1143-9. [PMID: 32217940 DOI: 10.1097/TP.0000000000003196] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
91 Grąt M, Krasnodębski M, Krawczyk M, Stypułkowski J, Morawski M, Wasilewicz M, Lewandowski Z, Grąt K, Patkowski W, Zieniewicz K. Extremes of Liver Transplantation for Hepatocellular Carcinoma. J Clin Med 2019;8:E787. [PMID: 31163668 DOI: 10.3390/jcm8060787] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
92 Lai Q, Rossi M. Survivals after liver transplantation for hepatocellular carcinoma: Granular data for a better allocation process? Hepatobiliary Pancreat Dis Int 2018;17:374-5. [PMID: 29866607 DOI: 10.1016/j.hbpd.2018.04.009] [Reference Citation Analysis]
93 Toso C, Meeberg G, Andres A, Shore C, Saunders C, Bigam DL, Shapiro AMJ, Compagnon P, Berney T, Majno P, Kneteman N. Downstaging prior to liver transplantation for hepatocellular carcinoma: advisable but at the price of an increased risk of cancer recurrence - a retrospective study. Transpl Int 2019;32:163-72. [PMID: 30152891 DOI: 10.1111/tri.13337] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
94 Reig M, Forner A, Ávila MA, Ayuso C, Mínguez B, Varela M, Bilbao I, Bilbao JI, Burrel M, Bustamante J, Ferrer J, Gómez MÁ, Llovet JM, De la Mata M, Matilla A, Pardo F, Pastrana MA, Rodríguez-Perálvarez M, Tabernero J, Urbano J, Vera R, Sangro B, Bruix J. Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. Med Clin (Barc) 2021;156:463.e1-463.e30. [PMID: 33461840 DOI: 10.1016/j.medcli.2020.09.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
95 Abdelrahim M, Esmail A, Abudayyeh A, Murakami N, Saharia A, McMillan R, Victor D, Kodali S, Shetty A, Nolte Fong JV, Moore LW, Heyne K, Gaber AO, Ghobrial RM. Transplant Oncology: An Evolving Field in Cancer Care. Cancers (Basel) 2021;13:4911. [PMID: 34638395 DOI: 10.3390/cancers13194911] [Reference Citation Analysis]
96 Ersan V, Barut B, Yilmaz S. The Timing of Liver Transplantation Following Downstaging: Wait of Not to Wait? J Gastrointest Cancer 2020;51:1152-6. [PMID: 32856230 DOI: 10.1007/s12029-020-00491-z] [Reference Citation Analysis]
97 Caviglia GP, Ciruolo M, Olivero A, Carucci P, Rolle E, Rosso C, Abate ML, Risso A, Ribaldone DG, Tandoi F, Saracco GM, Bugianesi E, Gaia S. Prognostic Role of Serum Cytokeratin-19 Fragment (CYFRA 21-1) in Patients with Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E2776. [PMID: 32998218 DOI: 10.3390/cancers12102776] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
98 Bonney GK, Chew CA, Lodge P, Hubbard J, Halazun KJ, Trunecka P, Muiesan P, Mirza DF, Isaac J, Laing RW, Iyer SG, Chee CE, Yong WP, Muthiah MD, Panaro F, Sanabria J, Grothey A, Moodley K, Chau I, Chan ACY, Wang CC, Menon K, Sapisochin G, Hagness M, Dueland S, Line PD, Adam R. Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines. Lancet Gastroenterol Hepatol 2021;6:933-46. [PMID: 34506756 DOI: 10.1016/S2468-1253(21)00219-3] [Reference Citation Analysis]
99 Galle PR, Foerster F, Kudo M, Chan SL, Llovet JM, Qin S, Schelman WR, Chintharlapalli S, Abada PB, Sherman M, Zhu AX. Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. Liver Int. 2019;39:2214-2229. [PMID: 31436873 DOI: 10.1111/liv.14223] [Cited by in Crossref: 60] [Cited by in F6Publishing: 68] [Article Influence: 20.0] [Reference Citation Analysis]
100 Wang P, Xu Y, Sun Y, Cheng J, Zhou K, Wu S, Hu B, Zhang Z, Guo W, Cao Y, Huang X, Zhou J, Fan J, Yang X. Detection of circulating tumour cells enables early recurrence prediction in hepatocellular carcinoma patients undergoing liver transplantation. Liver Int 2021;41:562-73. [DOI: 10.1111/liv.14734] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
101 Piñero F, Dirchwolf M, Pessôa MG. Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment. Cells 2020;9:E1370. [PMID: 32492896 DOI: 10.3390/cells9061370] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
102 Gitto S, Di Sandro S, Magistri P, Andreone P, Di Benedetto F. Hepatocellular carcinoma and liver transplant: beyond the Milan criteria and the risk of "short-blanket" syndrome. Hepatobiliary Surg Nutr 2020;9:518-21. [PMID: 32832508 DOI: 10.21037/hbsn.2019.11.34] [Reference Citation Analysis]
103 Cucchetti A, Serenari M. Efficacy of radiofrequency ablation of hepatocellular carcinoma prior to liver transplantation and the need for competing-risk analysis. Hepatobiliary Surg Nutr 2018;7:294-6. [PMID: 30221158 DOI: 10.21037/hbsn.2018.04.05] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
104 Masior Ł, Grąt M, Grąt K, Krasnodębski M, Wronka KM, Stypułkowski J, Patkowski W, Frączek M, Krawczyk M, Zieniewicz K. Importance of Intraoperative Transfusions of Packed Red Blood Cells and Fresh Frozen Plasma in Liver Transplantation for Hepatocellular Cancer. Ann Transplant 2020;25:e923665. [PMID: 33079923 DOI: 10.12659/AOT.923665] [Reference Citation Analysis]
105 Grąt K, Pacho R, Grąt M, Krawczyk M, Zieniewicz K, Rowiński O. Impact of Body Composition on the Risk of Hepatocellular Carcinoma Recurrence After Liver Transplantation. J Clin Med 2019;8:E1672. [PMID: 31614892 DOI: 10.3390/jcm8101672] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
106 Firl DJ, Sasaki K, Aucejo FN. Predicting Outcomes of Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma. Gastroenterology 2018;154:1856-7. [PMID: 29621517 DOI: 10.1053/j.gastro.2017.11.296] [Reference Citation Analysis]
107 Mourad M, Lebossé F, Merle P, Levrero M, Antonini T, Lesurtel M, Ducerf C, Zoulim F, Mabrut JY, Mohkam K. External validation of the French alpha-fetoprotein model for hepatocellular carcinoma liver transplantation in a recent unicentric cohort - a retrospective study. Transpl Int 2021;34:535-45. [PMID: 33449394 DOI: 10.1111/tri.13819] [Reference Citation Analysis]
108 Goldberg D, Mantero A, Newcomb C, Delgado C, Forde KA, Kaplan DE, John B, Nuchovich N, Dominguez B, Emanuel E, Reese PP. Predicting survival after liver transplantation in patients with hepatocellular carcinoma using the LiTES-HCC score. J Hepatol. 2021;74:1398-1406. [PMID: 33453328 DOI: 10.1016/j.jhep.2020.12.021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
109 Garuti F, Neri A, Avanzato F, Gramenzi A, Rampoldi D, Rucci P, Farinati F, Giannini EG, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Sacco R, Cabibbo G, Marra F, Mega A, Morisco F, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Missale G, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Brunetto MR, Trevisani F;  ITA. LI.CA study group. The changing scenario of hepatocellular carcinoma in Italy: an update.Liver Int. 2021;41:585-597. [PMID: 33219585 DOI: 10.1111/liv.14735] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
110 Maccali C, Chagas AL, Boin I, Quiñonez E, Marciano S, Vilatobá M, Varón A, Anders M, Hoyos Duque S, Lima AS, Menendez J, Padilla‐machaca M, Poniachik J, Zapata R, Maraschio M, Chong Menéndez R, Muñoz L, Arufe D, Figueroa R, Soza A, Fauda M, Perales SR, Vergara Sandoval R, Bermudez C, Beltran O, Arenas Hoyos I, Mccormack L, Mattera FJ, Gadano A, Parente García JH, Tani CM, Augusto Carneiro D’albuquerque L, Carrilho FJ, Silva M, Piñero F. Recurrence of hepatocellular carcinoma after liver transplantation: Prognostic and predictive factors of survival in a Latin American cohort. Liver Int 2021;41:851-62. [DOI: 10.1111/liv.14736] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
111 Na BG, Kim YK, Hwang S, Lee KJ, Park GC, Ahn CS, Kim KH, Moon DB, Ha TY, Song GW, Jung DH, Yang H, Yoon YI, Tak E, Park YH, Lee SG. Absence of association between pretransplant serum soluble programmed death protein-1 level and prognosis following living donor liver transplantation in patients with hepatocellular carcinoma. Medicine (Baltimore) 2021;100:e25640. [PMID: 33907121 DOI: 10.1097/MD.0000000000025640] [Reference Citation Analysis]
112 Fessas P, Kaseb A, Wang Y, Saeed A, Szafron D, Jun T, Dharmapuri S, Rafeh Naqash A, Muzaffar M, Navaid M, Khan U, Lee C, Bulumulle A, Yu B, Paul S, Nimkar N, Bettinger D, Benevento F, Hildebrand H, Pressiani T, Abugabal YI, Personeni N, Huang YH, Rimassa L, Ang C, Marron T, Pinato DJ. Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study. J Immunother Cancer 2020;8:e001033. [PMID: 32868393 DOI: 10.1136/jitc-2020-001033] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
113 Hibi T, Sapisochin G. What is transplant oncology? Surgery. 2019;165:281-285. [PMID: 30471780 DOI: 10.1016/j.surg.2018.10.024] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
114 Liang L, Wang MD, Zhang YM, Zhang WG, Zhang CW, Lau WY, Shen F, Pawlik TM, Huang DS, Yang T. Association of Postoperative Biomarker Response with Recurrence and Survival in Patients with Hepatocellular Carcinoma and High Alpha-Fetoprotein Expressions (>400 ng/ml). J Hepatocell Carcinoma 2021;8:103-18. [PMID: 33748017 DOI: 10.2147/JHC.S289840] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
115 Centonze L, Di Sandro S, Lauterio A, De Carlis R, Sgrazzutti C, Ciulli C, Vella I, Vicentin I, Incarbone N, Bagnardi V, Vanzulli A, De Carlis L. A retrospective single-centre analysis of the oncological impact of LI-RADS classification applied to Metroticket 2.0 calculator in liver transplantation: every nodule matters. Transpl Int 2021;34:1712-21. [PMID: 34448275 DOI: 10.1111/tri.13983] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
116 Grąt M, Stypułkowski J, Morawski M, Wronka KM, Wasilewicz M, Lewandowski Z, Grąt K, Wójcik Z, Patkowski W, Zieniewicz K. Shadows Behind Using Simple Risk Models in Selection of Hepatocellular Carcinoma Patients for Liver Transplantation. Ann Surg 2020;271:1124-31. [PMID: 30601254 DOI: 10.1097/SLA.0000000000003176] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
117 Kim B, Kahn J, Terrault NA. Liver transplantation as therapy for hepatocellular carcinoma. Liver Int 2020;40 Suppl 1:116-21. [PMID: 32077598 DOI: 10.1111/liv.14346] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
118 Tschuor C, Ferrarese A, Kuemmerli C, Dutkowski P, Burra P, Clavien PA;  Liver Allocation Study Group. Allocation of liver grafts worldwide - Is there a best system? J Hepatol. 2019;71:707-718. [PMID: 31199941 DOI: 10.1016/j.jhep.2019.05.025] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
119 Mueller M, Kalisvaart M, O'Rourke J, Shetty S, Parente A, Muller X, Isaac J, Muellhaupt B, Muiesan P, Shah T, Clavien PA, Schlegel A, Dutkowski P. Hypothermic Oxygenated Liver Perfusion (HOPE) Prevents Tumor Recurrence in Liver Transplantation From Donation After Circulatory Death.Ann Surg. 2020;272:759-765. [PMID: 32889870 DOI: 10.1097/SLA.0000000000004258] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
120 Rohr-Udilova N, Tsuchiya K, Timelthaler G, Salzmann M, Meischl T, Wöran K, Stift J, Herac M, Schulte-Hermann R, Peck-Radosavljevic M, Sieghart W, Eferl R, Jensen-Jarolim E, Trauner M, Pinter M. Morphometric Analysis of Mast Cells in Tumor Predicts Recurrence of Hepatocellular Carcinoma After Liver Transplantation. Hepatol Commun 2021;5:1939-52. [PMID: 34558826 DOI: 10.1002/hep4.1770] [Reference Citation Analysis]
121 Reig M, Forner A, Rimola J, Ferrer-Fábrega J, Burrel M, Garcia-Criado A, Kelley RK, Galle PR, Mazzaferro V, Salem R, Sangro B, Singal AG, Vogel A, Fuster J, Ayuso C, Bruix J. BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update. J Hepatol 2021:S0168-8278(21)02223-6. [PMID: 34801630 DOI: 10.1016/j.jhep.2021.11.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
122 Thuluvath PJ, To C, Amjad W. Role of Locoregional Therapies in Patients With Hepatocellular Cancer Awaiting Liver Transplantation. Am J Gastroenterol 2021;116:57-67. [PMID: 33110015 DOI: 10.14309/ajg.0000000000000999] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
123 Sposito C, Cucchetti A, Mazzaferro V. Assessing Competing Risks for Death Following Liver Transplantation for Hepatocellular Carcinoma. Dig Dis Sci 2019;64:1001-7. [DOI: 10.1007/s10620-019-05538-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
124 Koch C, Bette T, Waidmann O, Filmann N, Schrecker C, Trojan J, Weiler N, Vermehren J, Schnitzbauer AA, Bechstein WO, Zeuzem S, Herrmann E, Welker MW. AFP ratio predicts HCC recurrence after liver transplantation. PLoS One. 2020;15:e0235576. [PMID: 32614912 DOI: 10.1371/journal.pone.0235576] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
125 Ferre-aracil C, Lledó J, Aguilera L, Garcia-paredes A, Rodríguez-santiago E, Graus J, García-gonzález M, Nuño J, López-buenadicha A, López-hervás P, Rodríguez-gandía M, Gea F, Albillos A. Current allocation policy is favorable for patients with hepatocellular carcinoma waiting for liver transplantation. Digestive and Liver Disease 2018;50:1345-50. [DOI: 10.1016/j.dld.2018.04.024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
126 Lai Q, Sapisochin G, Lerut JP. Benefit of a Live Donor for Patients With Hepatocellular Carcinoma on the Waiting List-Reply. JAMA Surg 2021. [PMID: 34910117 DOI: 10.1001/jamasurg.2021.6373] [Reference Citation Analysis]
127 Petrowsky H, Fritsch R, Guckenberger M, De Oliveira ML, Dutkowski P, Clavien P. Modern therapeutic approaches for the treatment of malignant liver tumours. Nat Rev Gastroenterol Hepatol 2020;17:755-72. [DOI: 10.1038/s41575-020-0314-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 11.5] [Reference Citation Analysis]
128 Abreu P, Gorgen A, Griffiths C, Ivanics T, Sapisochin G. Downstaging and Expanded Criteria Hepatocellular Carcinoma Liver Transplantation. Curr Hepatology Rep 2019;18:400-7. [DOI: 10.1007/s11901-019-00492-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
129 Vibert E, Schwartz M, Olthoff KM. Advances in resection and transplantation for hepatocellular carcinoma. J Hepatol. 2020;72:262-276. [PMID: 31954491 DOI: 10.1016/j.jhep.2019.11.017] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 26.0] [Reference Citation Analysis]
130 Lai Q, Iesari S, Finkenstedt A, Hoppe-Lotichius M, Foguenne M, Lehner K, Otto G, Lerut J. Hepatocellular carcinoma recurrence after acute liver allograft rejection treatment: A multicenter European experience. Hepatobiliary Pancreat Dis Int 2019;18:517-24. [PMID: 31151807 DOI: 10.1016/j.hbpd.2019.05.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
131 Chang Y, Cho Y, Lee JH, Lee YB, Cho EJ, Yu SJ, Sinn DH, Kim BH, Kim SH, Yi NJ, Lee KW, Kim JM, Park JW, Kim YJ, Yoon JH, Joh JW, Suh KS. Comparison of Models for Tumor Recurrence after Liver Transplantation for the Patients with Hepatocellular Carcinoma: A Multicenter Long-Term Follow-Up Study. Cancers (Basel) 2019;11:E1295. [PMID: 31484287 DOI: 10.3390/cancers11091295] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
132 Di Sandro S, Bagnardi V, Cucchetti A, Lauterio A, De Carlis R, Benuzzi L, Danieli M, Botta F, Centonze L, Najjar M, De Carlis L. From a Philosophical Framework to a Valid Prognostic Staging System of the New "Comprehensive Assessment" for Transplantable Hepatocellular Carcinoma. Cancers (Basel) 2019;11:E741. [PMID: 31142035 DOI: 10.3390/cancers11060741] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
133 Kubal C, Mihaylov P, Holden J. Oncologic indications of liver transplantation and deceased donor liver allocation in the United States. Curr Opin Organ Transplant 2021;26:168-75. [PMID: 33650998 DOI: 10.1097/MOT.0000000000000866] [Reference Citation Analysis]
134 Ho CM, Lee CH, Lee MC, Zhang JF, Chen CH, Wang JY, Hu RH, Lee PH. Survival After Treatable Hepatocellular Carcinoma Recurrence in Liver Recipients: A Nationwide Cohort Analysis. Front Oncol 2020;10:616094. [PMID: 33598433 DOI: 10.3389/fonc.2020.616094] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
135 Iavarone M, Invernizzi F. Liver transplant for hepatocellular carcinoma: A heavyweight therapeutic option in need of a new policy on liver graft allocation. Dig Liver Dis 2018;50:1351-2. [PMID: 30316790 DOI: 10.1016/j.dld.2018.09.018] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
136 Mahmud N, John B, Taddei TH, Goldberg DS. Pre-transplant alpha-fetoprotein is associated with post-transplant hepatocellular carcinoma recurrence mortality. Clin Transplant. 2019;33:e13634. [PMID: 31177570 DOI: 10.1111/ctr.13634] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
137 Pinna AD, Yang T, Mazzaferro V, De Carlis L, Zhou J, Roayaie S, Shen F, Sposito C, Cescon M, Di Sandro S, Yi-Feng H, Johnson P, Cucchetti A. Liver Transplantation and Hepatic Resection can Achieve Cure for Hepatocellular Carcinoma. Ann Surg 2018;268:868-75. [PMID: 30080736 DOI: 10.1097/SLA.0000000000002889] [Cited by in Crossref: 51] [Cited by in F6Publishing: 26] [Article Influence: 17.0] [Reference Citation Analysis]
138 Mehta N, Yao FY. Living donor liver transplantation for hepatocellular carcinoma: To expand (beyond Milan) or downstage (to Milan)? Liver Transpl. 2018;24:327-329. [PMID: 29351366 DOI: 10.1002/lt.25017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
139 Lee SK, Lee SW, Jang JW, Bae SH, Choi JY, Yoon SK. Immunological Markers, Prognostic Factors and Challenges Following Curative Treatments for Hepatocellular Carcinoma. Int J Mol Sci 2021;22:10271. [PMID: 34638613 DOI: 10.3390/ijms221910271] [Reference Citation Analysis]
140 Moeckli B, Ivanics T, Claasen M, Toso C, Sapisochin G. Recent developments and ongoing trials in transplant oncology. Liver Int 2020;40:2326-44. [PMID: 33021344 DOI: 10.1111/liv.14621] [Reference Citation Analysis]
141 Nahon P, Aubé C, Moga L, Chalaye J, Guiu B, Luciani A, Rode A, Ronot M, Seror O, Soussan M, Sutter O, Bourlière M, Bureau C, de Lédinghen V, Ganne-Carrié N. NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF PRIMARY MALIGNANT LIVER TUMOURS. Clin Res Hepatol Gastroenterol 2021;:101766. [PMID: 34332137 DOI: 10.1016/j.clinre.2021.101766] [Reference Citation Analysis]
142 Cusumano C, De Carlis L, Centonze L, Lesourd R, Levi Sandri GB, Lauterio A, De Carlis R, Ferla F, Di Sandro S, Camus C, Jézéquel C, Bardou-Jacquet E, Rayar M. Advanced donor age does not increase risk of hepatocellular carcinoma recurrence after liver transplantation: a retrospective two-centre analysis using competing risk analysis. Transpl Int 2021. [PMID: 34145653 DOI: 10.1111/tri.13950] [Reference Citation Analysis]
143 Ivanics T, Nelson W, Patel MS, Claasen MPAW, Lau L, Gorgen A, Abreu P, Goldenberg A, Erdman L, Sapisochin G. The Toronto Postliver Transplantation Hepatocellular Carcinoma Recurrence Calculator: A Machine Learning Approach. Liver Transpl 2021. [PMID: 34626159 DOI: 10.1002/lt.26332] [Reference Citation Analysis]
144 Andres A, Oldani G, Berney T, Compagnon P, Line PD, Toso C. Transplantation for colorectal metastases: on the edge of a revolution. Transl Gastroenterol Hepatol. 2018;3:74. [PMID: 30363763 DOI: 10.21037/tgh.2018.08.04] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
145 Piñero F, Thompson M, Marín JI, Silva M. Lenvatinib as first-line therapy for recurrent hepatocellular carcinoma after liver transplantation: Is the current evidence applicable to these patients? World J Transplant 2020; 10(11): 297-306 [PMID: 33312891 DOI: 10.5500/wjt.v10.i11.297] [Cited by in CrossRef: 2] [Article Influence: 1.0] [Reference Citation Analysis]
146 Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primers 2021;7:6. [PMID: 33479224 DOI: 10.1038/s41572-020-00240-3] [Cited by in Crossref: 96] [Cited by in F6Publishing: 108] [Article Influence: 96.0] [Reference Citation Analysis]
147 Liu IT, Yen CS, Wang WL, Tsai HW, Chu CY, Chang MY, Hou YF, Yen CJ. Predict Early Recurrence of Resectable Hepatocellular Carcinoma Using Multi-Dimensional Artificial Intelligence Analysis of Liver Fibrosis. Cancers (Basel) 2021;13:5323. [PMID: 34771487 DOI: 10.3390/cancers13215323] [Reference Citation Analysis]
148 Cunha GM, Hosseini M, Furlan A, Fowler KJ. Hepatocellular Carcinoma Staging: Differences Between Radiologic and Pathologic Systems and Relevance to Patient Selection and Outcomes in Liver Transplantation. AJR Am J Roentgenol 2021;:1-10. [PMID: 34406054 DOI: 10.2214/AJR.21.26436] [Reference Citation Analysis]
149 Jiang YQ, Cao SE, Cao S, Chen JN, Wang GY, Shi WQ, Deng YN, Cheng N, Ma K, Zeng KN, Yan XJ, Yang HZ, Huan WJ, Tang WM, Zheng Y, Shao CK, Wang J, Yang Y, Chen GH. Preoperative identification of microvascular invasion in hepatocellular carcinoma by XGBoost and deep learning.J Cancer Res Clin Oncol. 2021;147:821-833. [PMID: 32852634 DOI: 10.1007/s00432-020-03366-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
150 Sahara K, Tsilimigras DI, Mehta R, Bagante F, Guglielmi A, Aldrighetti L, Alexandrescu S, Marques HP, Shen F, Koerkamp BG, Endo I, Pawlik TM. A novel online prognostic tool to predict long-term survival after liver resection for intrahepatic cholangiocarcinoma: The "metro-ticket" paradigm. J Surg Oncol 2019;120:223-30. [PMID: 31004365 DOI: 10.1002/jso.25480] [Cited by in Crossref: 3] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
151 Zhang Y, Zuo Z, Liu B, Yang P, Wu J, Han L, Han T, Chen T. FAT10 promotes hepatocellular carcinoma (HCC) carcinogenesis by mediating P53 degradation and acts as a prognostic indicator of HCC. J Gastrointest Oncol 2021;12:1823-37. [PMID: 34532131 DOI: 10.21037/jgo-21-374] [Reference Citation Analysis]
152 Kornberg A, Schernhammer M, Kornberg J, Friess H, Thrum K. Serological Risk Index Based on Alpha-Fetoprotein and C-Reactive Protein to Indicate Futile Liver Transplantation Among Patients with Advanced Hepatocellular Carcinoma. Dig Dis Sci 2019;64:269-80. [PMID: 30259282 DOI: 10.1007/s10620-018-5296-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
153 Bürger C, Maschmeier M, Hüsing-Kabar A, Wilms C, Köhler M, Schmidt M, Schmidt HH, Kabar I. Achieving Complete Remission of Hepatocellular Carcinoma: A Significant Predictor for Recurrence-Free Survival after Liver Transplantation. Can J Gastroenterol Hepatol 2019;2019:5796074. [PMID: 30729099 DOI: 10.1155/2019/5796074] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
154 Mazzaferro V, Citterio D, Bhoori S, Bongini M, Miceli R, De Carlis L, Colledan M, Salizzoni M, Romagnoli R, Antonelli B, Vivarelli M, Tisone G, Rossi M, Gruttadauria S, Di Sandro S, De Carlis R, Lucà MG, De Giorgio M, Mirabella S, Belli L, Fagiuoli S, Martini S, Iavarone M, Svegliati Baroni G, Angelico M, Ginanni Corradini S, Volpes R, Mariani L, Regalia E, Flores M, Droz Dit Busset M, Sposito C. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial. Lancet Oncol 2020;21:947-56. [PMID: 32615109 DOI: 10.1016/S1470-2045(20)30224-2] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 13.5] [Reference Citation Analysis]
155 Lee S, Kim KW, Song GW, Kwon JH, Hwang S, Kim KH, Ahn CS, Moon DB, Park GC, Lee SG. The Real Impact of Bridging or Downstaging on Survival Outcomes after Liver Transplantation for Hepatocellular Carcinoma. Liver Cancer 2020;9:721-33. [PMID: 33442541 DOI: 10.1159/000507887] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
156 Sternby Eilard M, Holmberg E, Naredi P, Söderdahl G, Rizell M. Addition of alfa fetoprotein to traditional criteria for hepatocellular carcinoma improves selection accuracy in liver transplantation. Scand J Gastroenterol 2018;53:976-83. [PMID: 30169974 DOI: 10.1080/00365521.2018.1488180] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
157 Duda DG, Dima SO, Cucu D, Sorop A, Klein S, Ancukiewicz M, Kitahara S, Iacob S, Bacalbasa N, Tomescu D, Herlea V, Tanase C, Croitoru A, Popescu I. Potential Circulating Biomarkers of Recurrence after Hepatic Resection or Liver Transplantation in Hepatocellular Carcinoma Patients. Cancers (Basel) 2020;12:E1275. [PMID: 32443546 DOI: 10.3390/cancers12051275] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
158 Pinato DJ, Guerra N, Fessas P, Murphy R, Mineo T, Mauri FA, Mukherjee SK, Thursz M, Wong CN, Sharma R, Rimassa L. Immune-based therapies for hepatocellular carcinoma. Oncogene 2020;39:3620-37. [PMID: 32157213 DOI: 10.1038/s41388-020-1249-9] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 23.5] [Reference Citation Analysis]
159 Chao JS, Zhao SL, Ou-yang SW, Qian YB, Liu AQ, Tang HM, Zhong L, Peng ZH, Xu JM, Sun HC. Post-transplant infection improves outcome of hepatocellular carcinoma patients after orthotopic liver transplantation. World J Gastroenterol 2019; 25(37): 5630-5640 [PMID: 31602163 DOI: 10.3748/wjg.v25.i37.5630] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
160 Panayotova G, Lunsford KE, Latt NL, Paterno F, Guarrera JV, Pyrsopoulos N. Expanding indications for liver transplantation in the era of liver transplant oncology. World J Gastrointest Surg 2021; 13(5): 392-405 [PMID: 34122730 DOI: 10.4240/wjgs.v13.i5.392] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
161 Orci LA, Combescure C, Fink M, Oldani G, Compagnon P, Andres A, Berney T, Toso C. Predicting recurrence of hepatocellular carcinoma after liver transplantation using a novel model that incorporates tumor and donor-related factors. Transpl Int 2021. [PMID: 34784081 DOI: 10.1111/tri.14161] [Reference Citation Analysis]
162 Ma KW, She WH, Chan ACY, Cheung TT, Fung JYY, Dai WC, Lo CM, Chok KSH. Validated model for prediction of recurrent hepatocellular carcinoma after liver transplantation in Asian population. World J Gastrointest Oncol 2019; 11(4): 322-334 [PMID: 31040897 DOI: 10.4251/wjgo.v11.i4.322] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
163 Palmer DH, Malagari K, Kulik LM. Role of locoregional therapies in the wake of systemic therapy. Journal of Hepatology 2020;72:277-87. [DOI: 10.1016/j.jhep.2019.09.023] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
164 Halazun KJ, Rosenblatt RE, Mehta N, Lai Q, Hajifathalian K, Gorgen A, Brar G, Sasaki K, Doyle MBM, Tabrizian P, Agopian VG, Najjar M, Ivanics T, Samstein B, Brown RS Jr, Emond JC, Yao F, Lerut J, Rossi M, Mennini G, Iesari S, Finkenstedt A, Schaefer B, Mittler J, Hoppe-Lotichius M, Quintini C, Aucejo F, Chapman W, Sapisochin G. Dynamic α-Fetoprotein Response and Outcomes After Liver Transplant for Hepatocellular Carcinoma. JAMA Surg 2021;156:559-67. [PMID: 33950167 DOI: 10.1001/jamasurg.2021.0954] [Reference Citation Analysis]
165 Lang H, Heinrich S, Bartsch F, Hüttl F, Baumgart J, Mittler J. [Surgical treatment of hepatic tumors-liver resection and transplantation]. Internist (Berl) 2020;61:147-57. [PMID: 32016491 DOI: 10.1007/s00108-020-00754-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
166 Schlegel A, Foley DP, Savier E, Flores Carvalho M, De Carlis L, Heaton N, Taner CB. Recommendations for Donor and Recipient Selection and Risk Prediction: Working Group Report From the ILTS Consensus Conference in DCD Liver Transplantation. Transplantation 2021;105:1892-903. [PMID: 34416750 DOI: 10.1097/TP.0000000000003825] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
167 Mehta N. Hepatocellular Carcinoma-How to Determine Therapeutic Options. Hepatol Commun 2020;4:342-54. [PMID: 32140653 DOI: 10.1002/hep4.1481] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
168 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236. [PMID: 29628281 DOI: 10.1016/j.jhep.2018.03.019] [Cited by in Crossref: 2122] [Cited by in F6Publishing: 1974] [Article Influence: 530.5] [Reference Citation Analysis]
169 Tsilimigras DI, Pawlik TM. Prognostication in hepatocellular carcinoma: is it a burden or a ticket? Br J Surg 2021;108:337-9. [PMID: 33734326 DOI: 10.1093/bjs/znaa167] [Reference Citation Analysis]
170 Chen YY, Chen CL, Lin CC, Wang CC, Liu YW, Li WF, Chen YH. Efficacy and Safety of Lenvatinib in Hepatocellular Carcinoma Patients with Liver Transplantation: A Case-Control Study. Cancers (Basel) 2021;13:4584. [PMID: 34572811 DOI: 10.3390/cancers13184584] [Reference Citation Analysis]
171 Tautenhahn HM, Rauchfuß F, Ali Deeb A, Bauschke A, Settmacher U. [Living related liver transplantation]. Chirurg 2020;91:926-33. [PMID: 32909072 DOI: 10.1007/s00104-020-01268-7] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
172 Yao FY, Fidelman N, Mehta N. The Key Role of Staging Definitions for Assessment of Downstaging for Hepatocellular Carcinoma. Semin Liver Dis 2021;41:117-27. [PMID: 33788207 DOI: 10.1055/s-0040-1716565] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
173 Finotti M, Vitale A, Volk M, Cillo U. A 2020 update on liver transplant for hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2020;14:885-900. [PMID: 32662680 DOI: 10.1080/17474124.2020.1791704] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
174 Lang SA, Bednarsch J, Czigany Z, Joechle K, Kroh A, Amygdalos I, Strnad P, Bruns T, Heise D, Ulmer F, Neumann UP. Liver transplantation in malignant disease. World J Clin Oncol 2021; 12(8): 623-645 [PMID: 34513597 DOI: 10.5306/wjco.v12.i8.623] [Reference Citation Analysis]
175 Li WF, Yen YH, Liu YW, Wang CC, Yong CC, Lin CC, Cheng YF, Wang JH, Lu SN. Preoperative predictors of early recurrence after resection for hepatocellular carcinoma. Am J Surg 2021:S0002-9610(21)00471-2. [PMID: 34399978 DOI: 10.1016/j.amjsurg.2021.08.012] [Reference Citation Analysis]
176 Sapisochin G, Hibi T, Toso C, Man K, Berenguer M, Heimbach J, Greten TF, Pugh TJ, Dawson LA, Mazzaferro V. Transplant Oncology in Primary and Metastatic Liver Tumors: Principles, Evidence, and Opportunities. Ann Surg 2021;273:483-93. [PMID: 33065633 DOI: 10.1097/SLA.0000000000004071] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
177 Foerster F, Hoppe-Lotichius M, Vollmar J, Marquardt JU, Weinmann A, Wörns MA, Otto G, Zimmermann T, Galle PR. Long-term observation of hepatocellular carcinoma recurrence after liver transplantation at a European transplantation centre. United European Gastroenterol J 2019;7:838-49. [PMID: 31316788 DOI: 10.1177/2050640619840221] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
178 Zhang F, Jia Y, Zheng X, Shao D, Zhao Y, Wang Z, Dawulieti J, Liu W, Sun M, Sun W, Pan Y, Cui L, Wang Y, He K, Zhang M, Li J, Dong WF, Chen L. Janus nanocarrier-based co-delivery of doxorubicin and berberine weakens chemotherapy-exacerbated hepatocellular carcinoma recurrence. Acta Biomater 2019;100:352-64. [PMID: 31563690 DOI: 10.1016/j.actbio.2019.09.034] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
179 Lai Q, Vitale A, Halazun K, Iesari S, Viveiros A, Bhangui P, Mennini G, Wong T, Uemoto S, Lin CC, Mittler J, Ikegami T, Zhe Y, Zheng SS, Soejima Y, Hoppe-Lotichius M, Chen CL, Kaido T, Lo CM, Rossi M, Soin AS, Finkenstedt A, Emond JC, Cillo U, Lerut J. Identification of an Upper Limit of Tumor Burden for Downstaging in Candidates with Hepatocellular Cancer Waiting for Liver Transplantation: A West-East Collaborative Effort. Cancers (Basel) 2020;12:E452. [PMID: 32075133 DOI: 10.3390/cancers12020452] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
180 Miao W, Nie P, Yang G, Wang Y, Yan L, Zhao Y, Yu T, Yu M, Wu F, Rao W, Wang Z. An FDG PET/CT metabolic parameter-based nomogram for predicting the early recurrence of hepatocellular carcinoma after liver transplantation. Eur J Nucl Med Mol Imaging 2021. [PMID: 33813592 DOI: 10.1007/s00259-021-05328-w] [Reference Citation Analysis]
181 Wang S, Xiong Z, Liu Y, Leng Y, Deng H, Shen D, Meng X, Liu T. Efficacy and safety of acupuncture and moxibustion combined with the external application of traditional Chinese medicine in the treatment of primary liver cancer: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e27659. [PMID: 34713860 DOI: 10.1097/MD.0000000000027659] [Reference Citation Analysis]
182 Usta S, Kayaalp C. Tumor Diameter for Hepatocellular Carcinoma: Why Should Size Matter? J Gastrointest Cancer 2020;51:1114-7. [PMID: 32851543 DOI: 10.1007/s12029-020-00483-z] [Reference Citation Analysis]
183 Moeckli B, Majno P, Orci LA, Peloso A, Toso C. Liver Transplantation Selection and Allocation Criteria for Hepatocellular Carcinoma: A European Perspective. Semin Liver Dis 2021;41:172-81. [PMID: 33957694 DOI: 10.1055/s-0041-1723032] [Reference Citation Analysis]
184 Costentin CE, Bababekov YJ, Zhu AX, Yeh H. Is It Time to Reconsider the Milan Criteria for Selecting Patients With Hepatocellular Carcinoma for Deceased-Donor Liver Transplantation? Hepatology 2019;69:1324-36. [DOI: 10.1002/hep.30278] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
185 Piñero F, Anders M, Boin IF, Chagas A, Quiñonez E, Marciano S, Vilatobá M, Santos L, Hoyos Duque S, Lima AS, Menendez J, Padilla M, Poniachik J, Zapata R, Soza A, Maraschio M, Chong Menéndez R, Muñoz L, Arufe D, Figueroa R, de Ataide EC, Maccali C, Vergara Sandoval R, Bermudez C, Podesta LG, McCormack L, Varón A, Gadano A, Mattera J, Villamil F, Rubinstein F, Carrilho F, Silva M. Liver transplantation for hepatocellular carcinoma: impact of expansion criteria in a multicenter cohort study from a high waitlist mortality region. Transpl Int 2021;34:97-109. [PMID: 33040420 DOI: 10.1111/tri.13767] [Reference Citation Analysis]
186 Verna EC, Patel YA, Aggarwal A, Desai AP, Frenette C, Pillai AA, Salgia R, Seetharam A, Sharma P, Sherman C, Tsoulfas G, Yao FY. Liver transplantation for hepatocellular carcinoma: Management after the transplant. Am J Transplant 2020;20:333-47. [PMID: 31710773 DOI: 10.1111/ajt.15697] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 7.7] [Reference Citation Analysis]
187 Heimbach JK. Evolution of Liver Transplant Selection Criteria and U.S. Allocation Policy for Patients with Hepatocellular Carcinoma. Semin Liver Dis 2020;40:358-64. [PMID: 32942324 DOI: 10.1055/s-0040-1709492] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
188 Forner A, Da Fonseca LG, Díaz-González Á, Sanduzzi-Zamparelli M, Reig M, Bruix J. Controversies in the management of hepatocellular carcinoma. JHEP Rep 2019;1:17-29. [PMID: 32039350 DOI: 10.1016/j.jhepr.2019.02.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
189 Ivanics T, Patel MS, Erdman L, Sapisochin G. Artificial intelligence in transplantation (machine-learning classifiers and transplant oncology). Curr Opin Organ Transplant 2020;25:426-34. [PMID: 32487887 DOI: 10.1097/MOT.0000000000000773] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
190 Laube R, Sabih AH, Strasser SI, Lim L, Cigolini M, Liu K. Palliative care in hepatocellular carcinoma.J Gastroenterol Hepatol. 2021;36:618-628. [PMID: 32627853 DOI: 10.1111/jgh.15169] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
191 Pelizzaro F, Gambato M, Gringeri E, Vitale A, Cillo U, Farinati F, Burra P, Russo FP. Management of Hepatocellular Carcinoma Recurrence after Liver Transplantation. Cancers (Basel) 2021;13:4882. [PMID: 34638365 DOI: 10.3390/cancers13194882] [Reference Citation Analysis]
192 Ferrer-Fàbrega J, Sampson-Dávila J, Forner A, Sapena V, Díaz A, Vilana R, Navasa M, Fondevila C, Miquel R, Ayuso C, García-Valdecasas JC, Bruix J, Reig M, Fuster J. Limited tumour progression beyond Milan criteria while on the waiting list does not result in unacceptable impairment of survival. J Hepatol 2021:S0168-8278(21)00435-9. [PMID: 34171433 DOI: 10.1016/j.jhep.2021.06.015] [Reference Citation Analysis]
193 Hoffman D, Mehta N. Recurrence of hepatocellular carcinoma following liver transplantation. Expert Rev Gastroenterol Hepatol 2021;15:91-102. [PMID: 32933351 DOI: 10.1080/17474124.2021.1823213] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
194 Mehta N, Yao FY. What Are the Optimal Liver Transplantation Criteria for Hepatocellular Carcinoma? Clin Liver Dis (Hoboken) 2019;13:20-5. [PMID: 31168361 DOI: 10.1002/cld.793] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
195 Philips CA, Rajesh S, Nair DC, Ahamed R, Abduljaleel JK, Augustine P. Hepatocellular Carcinoma in 2021: An Exhaustive Update. Cureus 2021;13:e19274. [PMID: 34754704 DOI: 10.7759/cureus.19274] [Reference Citation Analysis]
196 Claasen MPAW, Ivanics T, Gravely A, Sapisochin G. Prognostic risk scores for liver transplantation: game changers or statistical artworks? Hepatobiliary Surg Nutr 2021;10:553-7. [PMID: 34430542 DOI: 10.21037/hbsn-21-258] [Reference Citation Analysis]
197 Rojas-Pintor KP, Arizmendi-Villarreal MA, Aparicio-Salas JE, Moreno-Peña DP, Hernández-Barajas D, Cordero-Pérez P, Muñoz-Espinosa LE. Differences in the presentation and treatment of primary liver tumors at a hepatology center and an oncology center. Rev Gastroenterol Mex (Engl Ed) 2021:S0375-0906(21)00002-1. [PMID: 33676785 DOI: 10.1016/j.rgmx.2020.08.005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
198 Bhat M, Clotet-Freixas S, Baciu C, Pasini E, Hammad A, Ivanics T, Reid S, Azhie A, Angeli M, Ghanekar A, Fischer S, Sapisochin G, Konvalinka A. Combined proteomic/transcriptomic signature of recurrence post-liver transplantation for hepatocellular carcinoma beyond Milan. Clin Proteomics 2021;18:27. [PMID: 34794390 DOI: 10.1186/s12014-021-09333-x] [Reference Citation Analysis]
199 Li WF, Yen YH, Liu YW, Wang CC, Yong CC, Lin CC, Cheng YF, Wang JH. Validation of an alpha-fetoprotein model to predict recurrence after liver resection for hepatocellular carcinoma. Updates Surg 2021. [PMID: 34374920 DOI: 10.1007/s13304-021-01147-8] [Reference Citation Analysis]
200 Piñero F, Tanno M, Aballay Soteras G, Tisi Baña M, Dirchwolf M, Fassio E, Ruf A, Mengarelli S, Borzi S, Fernández N, Ridruejo E, Descalzi V, Anders M, Mazzolini G, Reggiardo V, Marciano S, Perazzo F, Spina JC, McCormack L, Maraschio M, Lagues C, Gadano A, Villamil F, Silva M, Cairo F, Ameigeiras B; Argentinean Association for the Study of Liver Diseases (A.A.E.E.H). Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma. Ann Hepatol 2020;19:546-69. [PMID: 32593747 DOI: 10.1016/j.aohep.2020.06.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
201 Rojas-Pintor KP, Arizmendi-Villarreal MA, Aparicio-Salas JE, Moreno-Peña DP, Hernández-Barajas D, Cordero-Pérez P, Muñoz-Espinosa LE. Differences in the presentation and treatment of primary liver tumors at a hepatology center and an oncology center. Rev Gastroenterol Mex (Engl Ed) 2021:S2255-534X(21)00080-3. [PMID: 34384724 DOI: 10.1016/j.rgmxen.2021.07.006] [Reference Citation Analysis]